Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status approved
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII X6Q56QN5QC
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Back pain15.03.04.005--
Basal cell carcinoma16.03.02.001; 23.08.02.0010.000895%-
Bile duct stone09.02.02.0030.000112%-
Blepharitis06.04.04.001; 23.03.04.012---
Blister12.01.06.002; 23.03.01.001---
Blood creatinine increased13.13.01.004--
Blood iron decreased13.11.01.006---
Blood urea increased13.13.01.006---
Blood uric acid increased13.02.04.001---
Body temperature increased13.15.01.001---
Bone disorder15.02.04.0040.000112%-
Bowen's disease16.03.02.004; 23.08.02.0040.000672%-
Breast cancer16.10.01.001; 21.05.01.0030.000616%-
Bromosulphthalein test abnormal13.03.04.021---
Cardiac arrest02.03.04.0010.000392%
Cardiac failure02.05.01.0010.001007%
Cardiomegaly02.04.02.0010.000168%-
Cataract06.06.01.0010.000224%
Cerebral haemorrhage17.08.01.003; 24.07.04.0010.000560%-
Cerebral infarction17.08.01.004; 24.04.06.0020.001119%-
Chills08.01.09.001; 15.05.03.016--
Cholecystitis09.03.01.0010.000112%
Cholelithiasis09.03.01.0020.000280%-
Cholestasis09.01.01.0010.000112%-
Chromaturia20.02.01.0020.000112%
Chronic myeloid leukaemia01.10.07.001; 16.01.07.0010.000783%-
Colon cancer07.21.01.001; 16.13.01.0010.000504%-
Constipation07.02.02.001--
Cough22.02.03.0010.001007%
Cutaneous vasculitis10.02.02.003; 23.06.02.001; 24.12.04.0080.000112%-
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene